PRINCETON, N.J. , July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorbâ„¢-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.
PRINCETON, N.J. , June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device, (the denial letter).
AptarGroup (ATR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
![]() ATR In 3 weeks Estimated | Quarterly | $0.45 Per Share |
![]() ATR 2 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 5 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 8 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 11 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 24 Apr 2024 Paid | Quarterly | $0.41 Per Share |
23 Jul 2025 (In 2 weeks) Date | | 1.57 Cons. EPS | - EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 1.26 Cons. EPS | 1.52 EPS |
24 Oct 2024 Date | | 1.42 Cons. EPS | 1.49 EPS |
25 Jul 2024 Date | | 1.36 Cons. EPS | 1.37 EPS |
![]() ATR In 3 weeks Estimated | Quarterly | $0.45 Per Share |
![]() ATR 2 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 5 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 8 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 11 months ago Paid | Quarterly | $0.45 Per Share |
![]() ATR 24 Apr 2024 Paid | Quarterly | $0.41 Per Share |
23 Jul 2025 (In 2 weeks) Date | | 1.57 Cons. EPS | - EPS |
23 Apr 2025 Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 1.26 Cons. EPS | 1.52 EPS |
24 Oct 2024 Date | | 1.42 Cons. EPS | 1.49 EPS |
25 Jul 2024 Date | | 1.36 Cons. EPS | 1.37 EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | Stephan B. Tanda CEO | CXA Exchange | US0383361039 ISIN |
US Country | 13,000 Employees | 5 Feb 2025 Last Dividend | 10 May 2007 Last Split | 21 Apr 1993 IPO Date |
AptarGroup, Inc. is at the forefront of designing and manufacturing innovative solutions for drug delivery, consumer product dispensing, and active material science. With a diverse portfolio aimed at meeting the needs of various markets such as pharmaceuticals, beauty, personal care, home care, and food and beverage, AptarGroup emphasizes its commitment to addressing consumer demands and industry challenges. Operating through three primary segments - Aptar Pharma, Aptar Beauty, and Aptar Closures, the company showcases a multifaceted approach to delivering excellence and innovation. Since its incorporation in 1992, AptarGroup has established a significant global presence, actively serving customers across Asia, Europe, Latin America, and North America from its headquarters in Crystal Lake, Illinois. This extensive footprint underscores its dedication to accessibility and service excellence worldwide.
The comprehensive range of products and services offered by AptarGroup caters to a wide array of market needs, ensuring high-quality, innovative solutions that enhance user experience and functionality. Here's a closer look at their offerings: